re: AUPH - Aurinia Pharmaceuticals

I am intrigued by this stock.

Anyone know how fast funds transfer from managed accounts to personal trading on fidelity?

If anyone is interested, earnings call at 3:30 ET.

+1-877-407-9170

Outlook changed my time

Only lost 4 cents a share instead of the expected 15

When a pharmaceutical is in the Research and Development stage, like AUPH, they start with a pile of cash (hopefully), and burn through a significant amount each quarter.

The ability of management to hold onto their cash instead of wreckless spending should provide much confidence in investors.

In short, Aurinia is a well run company.

Earnings calls will be underwhelming until results are released on their drugs. Sounds like they have a good group at the helm. Funded until 2020 so, see you guys at the Lambo dealership in 2020.

Just a general question when financial firms publish a target price. Do they come with a date attached or just a general buy rating to 16 dollars a share for the moment?

Listened to the call and have been following the voclosporin drugs. As I understand it they still working it towards FDA approval for Lupus Nephritis treatment sometime in 2020-2021.

Another question is what is the agreement with Merck for the dry eye treatment in dogs? Was it a one time deal or a portion of sales thing with Merck?

quote:

---

This happened in April 2017 so the initial cash from Merck happened in Q2 or Q3 of 2017

---

I remember it being a very small amount. The main thing that sticks out in that paragraph is Aurinia retaining all human health rights.

quote:

---

Zacks Investment Research, Inc. downgrades AURINIA PHARMACEUTICALS INC from HOLD to SELL. BY Investars Analyst Actions - private — 7:33 AM ET 03/20/2018 On March 20, 2018 Zacks Investment Research, Inc. downgraded AURINIA PHARMACEUTICALS INC ( AUPH Loading... Loading... ) from HOLD to SELL.

---

Seems like a lot of people jumped on this rating. Sales volume is up big over prior 5 days. Hoping this bottoms out and pick up some additional shares prior to close.

quote:

---

I remember it being a very small amount. The main thing that sticks out in that paragraph is Aurinia retaining all human health rights.

---

AUPH recorded licensing revenue of $418,000 for the year ended December 31, 2017 compared to $118,000 for the year ended December 31, 2016.

The increase in licensing revenue was the result of receiving $300,000 from Merck Animal Health ("MAH") in 2017. MAH entered into an agreement with AUPH on April 17, 2017 whereby AUPH granted MAH worldwide rights to develop and commercialize our patented nanomicellar voclosporin ophthalmic solution (“VOS”) for the treatment of Dry Eye Syndrome in dogs. Under the terms of the agreement, AUPH received a Technology Access fee of $300,000.

AUPH also recorded $118,000 in 2017 (2016-$118,000) as license revenue from the ongoing amortization of deferred revenue related to an upfront license payment of $1,500,000 received in 2010 pursuant to the 3Sbio Inc. license agreement. On August 23, 2010, AUPH and 3SBio, Inc. (3SBio) completed a Development, Distribution and License Agreement for voclosporin for the territories of China, Hong Kong and Taiwan. The transaction with 3SBio included a non-refundable licensing fee of $1,500,000, which was originally recorded as deferred revenue. At December 31, 2017 deferred revenue remaining to be amortized was $560,000 of which $118,000 was allocated to the current portion and $442,000 to the long-term portion. This deferred revenue is being amortized into licensing revenue on a straight line basis to 2022.